Literature DB >> 34325471

Surgery for Degenerative Cervical Myelopathy: A Nationwide Registry-Based Observational Study With Patient-Reported Outcomes.

Sasha Gulati1,2,3, Vetle Vangen-Lønne1,2, Øystein P Nygaard1,2,3, Agnete M Gulati4, Tommy A Hammer5, Tonje O Johansen1,2, Wilco C Peul6,7, Øyvind O Salvesen8, Tore K Solberg9,10.   

Abstract

BACKGROUND: Indications and optimal timing for surgical treatment of degenerative cervical myelopathy (DCM) remain unclear, and data from daily clinical practice are warranted.
OBJECTIVE: To investigate clinical outcomes following decompressive surgery for DCM.
METHODS: Data were obtained from the Norwegian Registry for Spine Surgery. The primary outcome was change in the neck disability index (NDI) 1 yr after surgery. Secondary endpoints were the European myelopathy score (EMS), quality of life (EuroQoL 5D [EQ-5D]), numeric rating scales (NRS) for headache, neck pain, and arm pain, complications, and perceived benefit of surgery assessed by the Global Perceived Effect (GPE) scale.
RESULTS: We included 905 patients operated between January 2012 and June 2018. There were significant improvements in all patient-reported outcome measures (PROMs) including NDI (mean -10.0, 95% CI -11.5 to -8.4, P < .001), EMS (mean 1.0, 95% CI 0.8-1.1, P < .001), EQ-5D index score (mean 0.16, 95% CI 0.13-0.19, P < .001), EQ-5D visual analogue scale (mean 13.8, 95% CI 11.7-15.9, P < .001), headache NRS (mean -1.1, 95% CI -1.4 to -0.8, P < .001), neck pain NRS (mean -1.8, 95% CI -2.0 to -1.5, P < .001), and arm pain NRS (mean -1.7, 95% CI -1.9 to -1.4, P < .001). According to GPE scale assessments, 229/513 patients (44.6%) experienced "complete recovery" or felt "much better" at 1 yr. There were significant improvements in all PROMs for both mild and moderate-to-severe DCM. A total of 251 patients (27.7%) experienced adverse effects within 3 mo.
CONCLUSION: Surgery for DCM is associated with significant and clinically meaningful improvement across a wide range of PROMs. © Congress of Neurological Surgeons 2021.

Entities:  

Keywords:  Cervical spine; Decompressive surgery; Degenerative; Degenerative cervical myelopathy; Observational study; Spine disorder; Spine surgery

Year:  2021        PMID: 34325471     DOI: 10.1093/neuros/nyab259

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Surgery for degenerative cervical myelopathy in patients with rheumatoid arthritis and ankylosing spondylitis: a nationwide registry-based study with patient-reported outcomes.

Authors:  Siril T Holmberg; Agnete M Gulati; Tonje Okkenhaug Johansen; Øyvind O Salvesen; Vetle Vangen Lønne; Tore K Solberg; Erling A Tronvik; Øystein P Nygaard; Sasha Gulati
Journal:  Acta Neurochir (Wien)       Date:  2022-10-15       Impact factor: 2.816

2.  Improvement rates, adverse events and predictors of clinical outcome following surgery for degenerative cervical myelopathy.

Authors:  Eddie de Dios; Mats Laesser; Isabella M Björkman-Burtscher; Lars Lindhagen; Anna MacDowall
Journal:  Eur Spine J       Date:  2022-09-02       Impact factor: 2.721

3.  A nationwide study of patients operated for cervical degenerative disorders in public and private hospitals.

Authors:  Elisabet Danielsen; Christer Mjåset; Tor Ingebrigtsen; Sasha Gulati; Margreth Grotle; Jan Håkon Rudolfsen; Øystein P Nygaard; Tore K Solberg
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

4.  Cerebrospinal fluid pressure dynamics reveal signs of effective spinal canal narrowing in ambiguous spine conditions.

Authors:  Najmeh Kheram; Nikolai Pfender; Andrea Boraschi; Mazda Farshad; Vartan Kurtcuoglu; Armin Curt; Martin Schubert; Carl M Zipser
Journal:  Front Neurol       Date:  2022-08-09       Impact factor: 4.086

5.  Surgery for degenerative cervical myelopathy in the elderly: a nationwide registry-based observational study with patient-reported outcomes.

Authors:  Tonje Okkenhaug Johansen; Vetle Vangen-Lønne; Siril T Holmberg; Øyvind O Salvesen; Tore K Solberg; Agnete M Gulati; Øystein P Nygaard; Sasha Gulati
Journal:  Acta Neurochir (Wien)       Date:  2022-07-19       Impact factor: 2.816

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.